Cargando…
Clinical potential of apremilast in the treatment of psoriatic arthritis
Psoriatic arthritis (PsA) is a frequent chronic inflammatory disease characterized by joint and skin involvement, and by typical extra-articular manifestations. Although the pathogenesis of PsA is still under investigation, the available evidence suggests the importance of the patient’s genetic back...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4918237/ https://www.ncbi.nlm.nih.gov/pubmed/27471702 http://dx.doi.org/10.2147/ITT.S40199 |
_version_ | 1782439085261979648 |
---|---|
author | Cauli, Alberto Porru, Giovanni Piga, Matteo Vacca, Alessandra Dessole, Grazia Mathieu, Alessandro |
author_facet | Cauli, Alberto Porru, Giovanni Piga, Matteo Vacca, Alessandra Dessole, Grazia Mathieu, Alessandro |
author_sort | Cauli, Alberto |
collection | PubMed |
description | Psoriatic arthritis (PsA) is a frequent chronic inflammatory disease characterized by joint and skin involvement, and by typical extra-articular manifestations. Although the pathogenesis of PsA is still under investigation, the available evidence suggests the importance of the patient’s genetic background, microbial or environmental triggers, and an imbalance in the adaptive and acquired immune system, resulting in the production of inflammatory mediators. New therapeutic approaches have been proposed, among them the use of modulators of intracellular signals and gene transcription such as PDE4-inhibiting compounds, which are able to modulate the activity of transcription factors such as CREB and NF-κB and therefore the synthesis of inflammatory mediators, resulting in immunoregulation. This paper summarizes the mechanism of action of apremilast, a PDE4 inhibitor, and the clinical data available on its clinical efficacy and safety profile in the treatment of PsA patients. |
format | Online Article Text |
id | pubmed-4918237 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2014 |
publisher | Dove Medical Press |
record_format | MEDLINE/PubMed |
spelling | pubmed-49182372016-07-28 Clinical potential of apremilast in the treatment of psoriatic arthritis Cauli, Alberto Porru, Giovanni Piga, Matteo Vacca, Alessandra Dessole, Grazia Mathieu, Alessandro Immunotargets Ther Review Psoriatic arthritis (PsA) is a frequent chronic inflammatory disease characterized by joint and skin involvement, and by typical extra-articular manifestations. Although the pathogenesis of PsA is still under investigation, the available evidence suggests the importance of the patient’s genetic background, microbial or environmental triggers, and an imbalance in the adaptive and acquired immune system, resulting in the production of inflammatory mediators. New therapeutic approaches have been proposed, among them the use of modulators of intracellular signals and gene transcription such as PDE4-inhibiting compounds, which are able to modulate the activity of transcription factors such as CREB and NF-κB and therefore the synthesis of inflammatory mediators, resulting in immunoregulation. This paper summarizes the mechanism of action of apremilast, a PDE4 inhibitor, and the clinical data available on its clinical efficacy and safety profile in the treatment of PsA patients. Dove Medical Press 2014-06-09 /pmc/articles/PMC4918237/ /pubmed/27471702 http://dx.doi.org/10.2147/ITT.S40199 Text en © 2014 Cauli et al. This work is published by Dove Medical Press Limited, and licensed under Creative Commons Attribution – Non Commercial (unported, v3.0) License The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0/. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. |
spellingShingle | Review Cauli, Alberto Porru, Giovanni Piga, Matteo Vacca, Alessandra Dessole, Grazia Mathieu, Alessandro Clinical potential of apremilast in the treatment of psoriatic arthritis |
title | Clinical potential of apremilast in the treatment of psoriatic arthritis |
title_full | Clinical potential of apremilast in the treatment of psoriatic arthritis |
title_fullStr | Clinical potential of apremilast in the treatment of psoriatic arthritis |
title_full_unstemmed | Clinical potential of apremilast in the treatment of psoriatic arthritis |
title_short | Clinical potential of apremilast in the treatment of psoriatic arthritis |
title_sort | clinical potential of apremilast in the treatment of psoriatic arthritis |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4918237/ https://www.ncbi.nlm.nih.gov/pubmed/27471702 http://dx.doi.org/10.2147/ITT.S40199 |
work_keys_str_mv | AT caulialberto clinicalpotentialofapremilastinthetreatmentofpsoriaticarthritis AT porrugiovanni clinicalpotentialofapremilastinthetreatmentofpsoriaticarthritis AT pigamatteo clinicalpotentialofapremilastinthetreatmentofpsoriaticarthritis AT vaccaalessandra clinicalpotentialofapremilastinthetreatmentofpsoriaticarthritis AT dessolegrazia clinicalpotentialofapremilastinthetreatmentofpsoriaticarthritis AT mathieualessandro clinicalpotentialofapremilastinthetreatmentofpsoriaticarthritis |